Definition
- Episodic or continuous abdominal pain occurring at least 4 times per month for a minimum of 2 months.
- Absence of identifiable inflammatory, anatomic, metabolic, or neoplastic processes explaining symptoms.
- Classified under disorders of gut-brain interaction (DGBI) via Rome IV criteria.
- Pain severity mimics organic disease; distress is genuine.
Pathophysiology
- Driven by biopsychosocial model integrating genetics, environment, and psychosocial factors.
- Visceral hyperalgesia: Altered, excessive perception of normal gut motility interpreted as pain.
- Brain-gut axis dysfunction: Abnormal bidirectional communication between enteric nervous system and central nervous system.
- Sensitization triggered by prior gastrointestinal infections, inflammation, cow milk allergy, or psychological trauma.
- Gut microbiota alterations and immune mucosal dysfunction influence pain thresholds.
Rome IV Classification Subtypes
| Subtype | Core Clinical Criteria |
|---|
| Functional abdominal pain - not otherwise specified | Episodic/continuous periumbilical pain; insufficient criteria for other functional disorders. |
| Irritable bowel syndrome | Pain associated with defecation, change in stool frequency, or change in stool form/appearance. |
| Functional dyspepsia | Postprandial fullness, early satiety, or epigastric pain/burning unrelated to defecation. |
| Abdominal migraine | Paroxysmal, intense periumbilical/midline pain lasting >1 hour; associated with anorexia, nausea, vomiting, headache, photophobia, pallor. |
Clinical Evaluation
Alarm Signs (Red Flags)
Absence of alarm signs permits symptom-based diagnosis without extensive invasive testing. Presence dictates targeted investigation.
| Category | Alarm Features |
|---|
| Systemic/Growth | Involuntary weight loss, linear growth deceleration, delayed puberty, unexplained fever. |
| Gastrointestinal | Gastrointestinal blood loss (hematochezia, occult), severe chronic or nocturnal diarrhea, dysphagia, persistent vomiting. |
| Pain Characteristics | Pain awakening child from sleep, persistent right upper or right lower quadrant pain, radiation to back/shoulder. |
| Physical/Family History | Perianal fistulae/tags, arthritis, hepatosplenomegaly, family history of inflammatory bowel disease or celiac disease. |
Directed Investigations
- Restrict testing if typical functional features exist lacking red flags.
- Screening panel: Complete blood count, erythrocyte sedimentation rate, C-reactive protein, comprehensive metabolic panel.
- Celiac screening: Tissue transglutaminase IgA, total serum IgA.
- Stool assays: Fecal calprotectin (differentiates functional pain from inflammatory bowel disease), occult blood, ova/parasites.
- Avoid routine abdominal ultrasonography or endoscopy unless indicated by specific alarm symptoms.
Management Strategies
Psychosocial And Behavioral Interventions
- Validate symptoms; explain brain-gut axis and visceral hyperalgesia concepts using simple analogies.
- Provide reassurance regarding benign, non-progressive disease nature.
- Normalize lifestyle; mandate return to school; minimize secondary gain and excessive parental attention to pain behaviors.
- Utilize cognitive behavioral therapy, gut-directed hypnotherapy, mindfulness, and relaxation techniques to improve coping skills.
Dietary Modifications
- Maintain well-balanced, age-appropriate nutrition with adequate fiber.
- Limit carbonated beverages, excessive fruit juices (fructose/sorbitol), and refined foods to reduce bloating.
- Trial low-FODMAP (fermentable oligo-, di-, monosaccharides, and polyols) diet for pain associated with severe bloating.
Pharmacotherapy
| Agent Class | Specific Therapies And Indications |
|---|
| Antispasmodics | Peppermint oil, hyoscyamine; target smooth muscle spasms in irritable bowel syndrome. |
| Probiotics | Lactobacillus rhamnosus GG; moderately increases treatment success, restores altered gut flora. |
| Neuromodulators | Amitriptyline (tricyclic antidepressant) or citalopram (SSRI); reserved for refractory, disabling pain with comorbid anxiety/depression. |
| Cyproheptadine | Enhances gastric accommodation in functional dyspepsia; useful for early satiety and nausea. |